Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype.
Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. · 2018
Read Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. by Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5934392.txt.
Introduction
Oh and a large team of co-authors map the gene and health traits of one type of stomach cancer. Their study was published in Nature Communications. Stomach cancer varies a lot, so drug response is hard to foresee. The team split tumours into two groups by their gene traits. One group has traits of skin-like cells. The other has traits of soft tissue cells.
The soft tissue group had few gene faults, the authors report. Its patients lived less long and shrugged off standard drug care. The skin-like group did better on those drugs. A growth signal path was very busy in the soft tissue group. Blocking that path hit those cells hard. The two groups may guide care choices.
Catalog record
| CREATOR | Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype By Sang Cheul Oh, Bo Hwa Sohn, Jae-Ho Cheong, Sang-Bae Kim, Jae Eun Lee, Ki Cheong Park, Sang Ho Lee, Jong-Lyul Park, Yun-Yong Park, Hyun-Sung Lee, Hee-Jin Jang, Eun Sung Park Published in: Nature Communications DOI: 10.1038/s41467-018-04179-8 ABSTRACT Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict. Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype (MP) and epithelial phenotype (EP), by analyzing genomic and proteomic data. Molecularly, MP subtype tumors show high genomic integrity characterized by low mutation rates and microsatellite stability, whereas EP subtype tumors show low genomic integrity. Clinically, the MP subtype is associated with markedly poor survival and resistance to standard chemotherapy, whereas the EP subtype is associated with better survival rates and sensitivity to chemotherapy. Integrative analysis shows that signaling pathways driving epithelial-to-mesenchymal transition and insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1R) pathway are highly activated in MP subtype tumors. Importantly, MP subtype cancer cells are more sensitive to inhibition of IGF1/IGF1R pathway than EP subtype. Detailed characterization of these two subtypes could identify novel therapeutic targets and useful biomarkers for prognosis and therapy response. INTRODUCTION Gastric cancer is the third leading cause of cancer-related death and the fifth most commonly diagnosed cancer in the world1. Although surgery is frequently recommended for localized gastric cancer2, the benefit from surgery alone is limited to patients with relatively early-stage disease. To prevent recurrence and improve the survival rates of patients after surgery, multimodal therapies, including chemoradiation and chemotherapy, have been established3. However, such treatments have improved cure rates by only ~10% and have increased toxicity. Both preoperative chemotherapy and postoperative chemoradiation chemotherapy have shown benefit over surgery alone4–6. However, >50% of patients still succumb to their cancer. Even with the advent of adjunctive therapies, however, the optimal approach for an individual patient or subset of patients is difficult to determine3. There is considerable clinicopathologic heterogeneity among tumors and outcomes among patients considered to have similar clinical or pathologic disease remain unpredictable7,8. This inherent clinical heterogeneity is consistent with the biological differences among patients with gastric cancer. During the course of tumor progression, cancer cells with an epithelial origin frequently acquire a mesenchymal phenotype through epithelial-to-mesenchymal transition (EMT), which is a physiologic process in which epithelial cells acquire phenotypic, motile, and invasive characteristics of mesenchymal cells9,10. EMT can be mediated by many different signaling pathways, including the transforming growth factor (TGF)-β pathway11. Although EMT is considered to be one of the biological features promoting clinical heterogeneity in gastric cancer12–14, the molecular and genetic characteristics of gastric cancer with an acquired mesenchymal phenotype and the clinicopathologic significance of these characteristics are not fully understood. In the current study, we used a genome-wide survey of gene expression data to uncover potential subtypes of gastric cancer that have distinct biological characteristics associated with prognosis, as well as signaling pathways enriched in each subtype that could serve as potential therapeutic targets. Here, we report that gastric cancers with a mesenchymal phenotype are associated with poor prognosis, markedly low somatic mutation rates and microsatellite instability (MSI), resistance to standard chemotherapy, and sensitive to inhibition of IGF1/IGF1R pathway. RESULTS Gene signature reflecting a mesenchymal phenotype We first performed unsupervised hierarchical clustering analysis using gene expression data from 93 human gastric cancer tissue samples from a Korea University Guro Hospital (KUGH) cohort (Supplementary Table 1) to uncover potential gastric cancer subtypes. To estimate the degree of heterogeneity among the tumors and between gastric cancer and non-gastric cancer in the stomach, we included in the microarray experiments and analysis three samples of gastrointestinal stromal tumor (GIST), the most common mesenchymal cancer in the gastrointestinal tract15, that had been located in the stomach. Unsupervised clustering revealed two distinct clusters (Fig. 1a): the small (S) cluster and the large (L) cluster. Interestingly, the three GIST tissue samples were co-clustered with samples in cluster S. The gastric cancer tissue samples in cluster S shared a considerable gene expression patterns with GIST tissue samples, indicating that the samples in cluster S potentially harbored biological characteristics similar to those of mesenchymal cells. Kaplan–Meier plots and log-rank tests indicated that patients whose tumor samples fell into the S cluster had significantly lower overall survival (OS) and recurrence-free survival (RFS) rates than did patients whose tumor samples fell into the L cluster (P = 0.007 for OS and 0.006 for RFS (Supplementary Table 1); Fig. 1b, c).Fig. 1Hierarchical clustering analysis of gene expression data from the Korea University Guro Hospital (KUGH) cohort. a Hierarchical clustering of gene expression data from 93 patients with gastric cancer and 3 patients with a gastrointestinal stromal tumor (GIST) located in the stomach in the KUGH cohort (n = 93). Genes with an expression level that had at least a twofold difference relative to the median value across tissues in at least 15 tissues were selected for hierarchical clustering analysis (3931 gene features). The data are presented in a matrix format in which each row represents an individual gene and each column represents a tissue sample. Each cell in the matrix represents the expression level of a gene feature in an individual tissue sample. The red and green coloring in the cells reflects relatively high and low expression levels, respectively, as indicated in the scale bar (log2 transformed scale). b, c Kaplan–Meier plots of the two gastric cancer clusters in the KUGH cohort (n = 93). The three patients with GIST were excluded for plotting. P values were obtained using the log-rank test. The + symbols indicate censored data. EP epithelial phenotype, MP mesenchymal phenotype, OS overall survival, RFS recurrence-free survival We next sought to identify genes whose expression was unique to the subtype identified by cluster S, and uncovered 299 genes with differential expression between the two clusters (Supplementary Fig. 1a and Supplementary Data 1). Gene network analysis revealed that the TGF-β pathway was the most significantly activated pathway in tumors in cluster S, as evidenced by increased expression of genes directly regulated by TGFB1, TGFB3, and SMAD3 (Supplementary Table 2 and Supplementary Fig. 2). Moreover, SMAD7, an inhibitor of the TGF-β pathway16, was significantly inactivated in the cluster S genetic signature, offering further supporting evidence that the TGF-β pathway was activated in tumors in cluster S. The TGF-β pathway is best known for inducing EMT12, suggesting that tumors in cluster S lost epithelial characteristics and acquired a mesenchymal phenotype. Moreover, gene network analysis revealed that α-catenin, a typical epithelial cell marker in the gut17, was the most significantly decreased RNA in tumors in cluster S (Supplementary Table 2). Given this finding, together with the similarity of the gene expression pattern in cluster S to that of the mesenchymal GIST samples, we referred to tumors in cluster S as mesenchymal phenotype (MP) and those in cluster L as epithelial phenotype (EP) gastric cancers (“MP subtype” and “EP subtype” hereafter). Validation of the MP subtype and its prognostic significance After identifying the MP genomic signature reflecting EMT and demonstrating its association with poor prognosis in patients with gastric cancer, we sought to validate the association of the MP subtype with prognosis in independent patient cohorts. For this validation, we used gene